What is Haemonetics Corporation (HAE)?

Haemonetics Corporation (HAE) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of HAE?

The current price of HAE is $118.32. Prices are updated in real time on Stocks360.

What is HAE's price-to-earnings (PE) ratio?

HAE's trailing twelve-month PE ratio is 57.44, based on current price and earnings per share data available on Stocks360.

What is HAE's market capitalization?

HAE's market capitalization is $5,383,205,040.00, placing it in the mid-cap tier.

Haemonetics Corporation (HAE)

Stock analysis · NYSE · Healthcare · Medical - Devices

$118.32

Market Cap

$5.38B

PE (TTM)

57.44

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.54

Day Range

$117.81 – $120.15

52-wk Range

$48.98 – $123.77

Avg Volume

N/A

Volume

501.80K

Haemonetics Corporation (HAE) is a publicly traded company in the Healthcare sector. Latest price: $118.32. Market cap $5.38B. Trailing PE 57.44. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $49.44 2026-10-28 · $118.32 (+139.32%)

Earnings

Most Recent

Aug 6, 2026

EPS $1.14 vs est. $1.08

Beat by $0.06

Next Earnings

Nov 5, 2026

EPS estimate $1.29

Proprietary Signals

Signal snapshot temporarily unavailable.

About Haemonetics Corporation

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	57.44×
P/S (TTM)	3.98×
P/B	6.41×
P/FCF (TTM)	18.49×
EV / EBITDA	24.25×
EV / Sales	4.68×
Earnings Yield	1.79%
Free Cash Flow Yield	5.41%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.33B
Revenue (TTM)	$1.35B
Net Income (TTM)	$96.58M
Free Cash Flow (TTM)	$253.62M
Net Debt	$950.77M
Working Capital	$547.60M
Gross Margin	57.38%
Operating Margin	18.18%
Net Margin	7.12%
Return on Equity	11.35%
Return on Invested Capital	8.61%